Skip to main content
. 2021 Sep 16;15:1291. doi: 10.3332/ecancer.2021.1291

Figure 2. (a): OS of the entire cohort. (b): PFS of the entire cohort. (c): Comparison of OS between pathologically node negative and node positive patients. (d): Comparison of PFS between CROSS eligible and CROSS ineligible patients.

Figure 2.